These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 947849)

  • 1. [A new influenza subunit vaccine: reactogenicity and antigenicity in comparison to split and whole virus vaccines (author's transl)].
    Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz A; SchmidtG
    Infection; 1976; 4(2):73-9. PubMed ID: 947849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Field trial with a new type of influenza subunit vaccine (author's transl)].
    Kunz C; Hofmann H
    Wien Klin Wochenschr; 1976 Aug; 88(15):504-8. PubMed ID: 997532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials with a new influenza subunit vaccine in adults and children.
    Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ
    Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new influenza subunit vaccine: hemagglutinating antibodies one year after vaccination (author's transl)].
    Kunz C; Hofmann H; Moritz A; Bachmayer H; Liehl E
    Infection; 1978; 6(5):217-20. PubMed ID: 365774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccination of infants and schoolchildren with an influenza subunit vaccine (author's transl)].
    Jürgenssen O; Moritz A; Liehl E; Bachmayer H
    Infection; 1978; 6(5):221-7. PubMed ID: 365775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers.
    Jennings R; Clark A; Oxford JS; Hockley DJ; Potter CW
    J Infect Dis; 1978 Nov; 138(5):577-86. PubMed ID: 712115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.
    Gross PA; Ennis FA; Gaerlan PF; Denson LJ; Denning CR; Schiffman D
    J Infect Dis; 1977 Nov; 136(5):623-32. PubMed ID: 335000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.
    Stephenson I; Nicholson KG; Glück R; Mischler R; Newman RW; Palache AM; Verlander NQ; Warburton F; Wood JM; Zambon MC
    Lancet; 2003 Dec; 362(9400):1959-66. PubMed ID: 14683655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical reactions and antibody responses to influenza vaccines. A comparison of split or subunit vaccines in children and young adults.
    Bernstein DI; Cherry JD
    Am J Dis Child; 1983 Jul; 137(7):622-6. PubMed ID: 6858973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
    Hartvickson R; Cruz M; Ervin J; Brandon D; Forleo-Neto E; Dagnew AF; Chandra R; Lindert K; Mateen AA
    Int J Infect Dis; 2015 Dec; 41():65-72. PubMed ID: 26585940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
    Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
    Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.
    Eastwood LM; Jennings R; Milner RD; Potter CW
    J Clin Pathol; 1979 Jun; 32(6):534-7. PubMed ID: 469010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.